lixivaptan has been researched along with uric acid in 1 studies
*Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN. [MeSH]
*Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN. [MeSH]
| Studies (lixivaptan) | Trials (lixivaptan) | Recent Studies (post-2010) (lixivaptan) | Studies (uric acid) | Trials (uric acid) | Recent Studies (post-2010) (uric acid) |
|---|---|---|---|---|---|
| 80 | 10 | 26 | 27,980 | 1,717 | 9,982 |
| Protein | Taxonomy | lixivaptan (IC50) | uric acid (IC50) |
|---|---|---|---|
| Solute carrier family 2, facilitated glucose transporter member 9 | Homo sapiens (human) | 300 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Decaux, G | 1 |
1 trial(s) available for lixivaptan and uric acid
| Article | Year |
|---|---|
Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985.
Topics: Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Diuresis; Humans; Hyponatremia; Inappropriate ADH Syndrome; Liver Cirrhosis; Osmolar Concentration; Potassium; Pyrroles; Sodium; Urea; Uric Acid; Water; Water-Electrolyte Balance | 2001 |